Literature DB >> 25303978

A tale of two receptors: insulin and insulin-like growth factor signaling in cancer.

Douglas Yee1.   

Abstract

Inhibition of the type I IGF receptor (IGF1R) has been the focus of numerous clinical trials. Two reports in this issue describe the results of phase I trials of an IGF1R tyrosine kinase inhibitor OSI-906. This commentary will describe the complex endocrine changes induced by these types of agents. ©2014 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25303978      PMCID： PMC4498265          DOI： 10.1158/1078-0432.CCR-14-2056

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  13 in total

1.  Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin.

Authors:  Hua Zhang; Alissa M Pelzer; David T Kiang; Douglas Yee
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

2.  Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor.

Authors:  Xianke Zeng; Hua Zhang; Annabell Oh; Yan Zhang; Douglas Yee
Journal:  Breast Cancer Res Treat       Date:  2011-08-18       Impact factor: 4.872

3.  Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo.

Authors:  Xianke Zeng; Deepali Sachdev; Hua Zhang; Martine Gaillard-Kelly; Douglas Yee
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

4.  Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes.

Authors:  Ruslan Novosyadlyy; Danielle E Lann; Archana Vijayakumar; Anne Rowzee; Deborah A Lazzarino; Yvonne Fierz; Joan M Carboni; Marco M Gottardis; Patricia A Pennisi; Alfredo A Molinolo; Naamit Kurshan; Wilson Mejia; Stefania Santopietro; Shoshana Yakar; Teresa L Wood; Derek LeRoith
Journal:  Cancer Res       Date:  2010-01-12       Impact factor: 12.701

5.  Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors.

Authors:  Paul Haluska; Heather M Shaw; Gretchen N Batzel; Donghua Yin; Julian R Molina; L Rhoda Molife; Timothy A Yap; M Luisa Roberts; Amarnath Sharma; Antonio Gualberto; Alex A Adjei; Johann S de Bono
Journal:  Clin Cancer Res       Date:  2007-10-01       Impact factor: 12.531

6.  Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors.

Authors:  Robin L Jones; Edward S Kim; Pilar Nava-Parada; Salma Alam; Faye M Johnson; Andrew W Stephens; Ronit Simantov; Srinivasu Poondru; Rich Gedrich; Scott M Lippman; Stan B Kaye; Craig P Carden
Journal:  Clin Cancer Res       Date:  2014-09-10       Impact factor: 12.531

7.  Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer.

Authors:  Corey J Langer; Silvia Novello; Keunchil Park; Maciej Krzakowski; Daniel D Karp; Tony Mok; Rebecca J Benner; Judith R Scranton; Anthony J Olszanski; Jacek Jassem
Journal:  J Clin Oncol       Date:  2014-06-02       Impact factor: 44.544

Review 8.  Biological effects of growth hormone on carbohydrate and lipid metabolism.

Authors:  Archana Vijayakumar; Ruslan Novosyadlyy; Yingjie Wu; Shoshana Yakar; Derek LeRoith
Journal:  Growth Horm IGF Res       Date:  2009-10-01       Impact factor: 2.372

9.  Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen.

Authors:  P M Ravdin; N F Fritz; D C Tormey; V C Jordan
Journal:  Cancer Res       Date:  1988-02-15       Impact factor: 12.701

10.  A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors.

Authors:  Igor Puzanov; Colin R Lindsay; Laura Goff; Jeff Sosman; Jill Gilbert; Jordan Berlin; Srinivasu Poondru; Ronit Simantov; Rich Gedrich; Andrew Stephens; Emily Chan; T R Jeffry Evans
Journal:  Clin Cancer Res       Date:  2014-09-11       Impact factor: 12.531
View more
  11 in total

1.  Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29.

Authors:  Judith-Anne W Chapman; Joseph P Costantino; Bin Dong; Richard G Margolese; Kathleen I Pritchard; Lois E Shepherd; Karen A Gelmon; Norman Wolmark; Michael N Pollak
Journal:  Breast Cancer Res Treat       Date:  2015-08-15       Impact factor: 4.872

2.  Insulin-like growth factor-related components and the risk of liver cancer in a nested case-control study.

Authors:  Yasushi Adachi; Masanori Nojima; Mitsuru Mori; Yasutaka Matsunaga; Noriyuki Akutsu; Shigeru Sasaki; Takao Endo; Youichi Kurozawa; Kenji Wakai; Akiko Tamakoshi
Journal:  Tumour Biol       Date:  2016-09-23

3.  Functional evolution of IGF2:IGF2R domain 11 binding generates novel structural interactions and a specific IGF2 antagonist.

Authors:  Susana Frago; Ryan D Nicholls; Madeleine Strickland; Jennifer Hughes; Christopher Williams; Lee Garner; Mirvat Surakhy; Rory Maclean; Dellel Rezgui; Stuart N Prince; Oliver J Zaccheo; Daniel Ebner; Sabina Sanegre; Sheng Yu; Francesca M Buffa; Matthew P Crump; Andrew Bassim Hassan
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-02       Impact factor: 11.205

4.  Analysis of Clinical and Molecular Factors Impacting Oncologic Outcomes in Undifferentiated Pleomorphic Sarcoma.

Authors:  Christina L Roland; Caitlin D May; Kelsey L Watson; Ghadah A Al Sannaa; Sean P Dineen; Rachel Feig; Sharon Landers; Davis R Ingram; Wei-Lien Wang; B Ashleigh Guadagnolo; Barry Feig; Kelly K Hunt; Janice N Cormier; Alexander J Lazar; Keila E Torres
Journal:  Ann Surg Oncol       Date:  2016-02-03       Impact factor: 5.344

5.  Insulin Receptor Substrate Suppression by the Tyrphostin NT157 Inhibits Responses to Insulin-Like Growth Factor-I and Insulin in Breast Cancer Cells.

Authors:  Yuzhe Yang; Jie Ying Chan; Nuri A Temiz; Douglas Yee
Journal:  Horm Cancer       Date:  2018-09-18       Impact factor: 3.869

Review 6.  Metabolic Strategies for Inhibiting Cancer Development.

Authors:  Philippe Icard; Mauro Loi; Zherui Wu; Antonin Ginguay; Hubert Lincet; Edouard Robin; Antoine Coquerel; Diana Berzan; Ludovic Fournel; Marco Alifano
Journal:  Adv Nutr       Date:  2021-07-30       Impact factor: 8.701

7.  Body Mass Index Influences the Prognostic Impact of Combined Nuclear Insulin Receptor and Estrogen Receptor Expression in Primary Breast Cancer.

Authors:  Sofie Björner; Ann H Rosendahl; Maria Simonsson; Andrea Markkula; Karin Jirström; Signe Borgquist; Carsten Rose; Christian Ingvar; Helena Jernström
Journal:  Front Endocrinol (Lausanne)       Date:  2017-11-28       Impact factor: 5.555

8.  Insulin-like growth factor-1, IGF binding protein-3, and the risk of esophageal cancer in a nested case-control study.

Authors:  Yasushi Adachi; Masanori Nojima; Mitsuru Mori; Kentaro Yamashita; Hiro-O Yamano; Hiroshi Nakase; Takao Endo; Kenji Wakai; Kiyomi Sakata; Akiko Tamakoshi
Journal:  World J Gastroenterol       Date:  2017-05-21       Impact factor: 5.742

Review 9.  Disrupting Insulin and IGF Receptor Function in Cancer.

Authors:  Jingran Cao; Douglas Yee
Journal:  Int J Mol Sci       Date:  2021-01-08       Impact factor: 5.923

10.  Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.

Authors:  Douglas Yee; Claudine Isaacs; Denise M Wolf; Christina Yau; Paul Haluska; Karthik V Giridhar; Andres Forero-Torres; A Jo Chien; Anne M Wallace; Lajos Pusztai; Kathy S Albain; Erin D Ellis; Heather Beckwith; Barbara B Haley; Anthony D Elias; Judy C Boughey; Kathleen Kemmer; Rachel L Yung; Paula R Pohlmann; Debu Tripathy; Amy S Clark; Hyo S Han; Rita Nanda; Qamar J Khan; Kristen K Edmiston; Emanuel F Petricoin; Erica Stringer-Reasor; Carla I Falkson; Melanie Majure; Rita A Mukhtar; Teresa L Helsten; Stacy L Moulder; Patricia A Robinson; Julia D Wulfkuhle; Lamorna Brown-Swigart; Meredith Buxton; Julia L Clennell; Melissa Paoloni; Ashish Sanil; Scott Berry; Smita M Asare; Amy Wilson; Gillian L Hirst; Ruby Singhrao; Adam L Asare; Jeffrey B Matthews; Nola M Hylton; Angela DeMichele; Michelle Melisko; Jane Perlmutter; Hope S Rugo; W Fraser Symmans; Laura J Van't Veer; Donald A Berry; Laura J Esserman
Journal:  NPJ Breast Cancer       Date:  2021-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.